Ciprofloxacin monotherapy for acute pelvic infections: a comparison with clindamycin plus gentamicin.
This prospective, randomized controlled study compared the efficacy and safety of ciprofloxacin alone versus a conventional two-drug regimen, clindamycin with gentamicin. The study group included 71 patients hospitalized for pelvic infections such as acute (N = 33) and chronic (N = 8) salpingitis, tubo-ovarian abscesses (N = 11), endometritis (N = 9), septic abortion (N = 3), and other categories (N = 7). Twenty-two of 35 patients on ciprofloxacin and 20 of 36 on clindamycin plus gentamicin had culturable pathogens: gonococci in 28, anaerobes in six, chlamydia in four, and associated pathogens in 19. Complete clinical and bacteriologic cure was achieved in 21 of 22 (95%) in the ciprofloxacin group and 19 of 20 (95%) in the clindamycin plus gentamicin group. The mean duration of intravenous/oral ciprofloxacin therapy was 3.7/7.2 days, and it was 3/6.6 days for clindamycin plus gentamicin. Ciprofloxacin, a new quinolone, appears to be safe as a single-drug therapy and was as effective as the combination of clindamycin plus gentamicin for the treatment of severe pelvic infections requiring hospitalization.
Department of Medicine, Charles R. Drew University of Medicine and Science, Martin Luther King Jr. General Hospital, Los Angeles, California.
H
H
Thadepalli
D
D
Mathai
R
R
Scotti
M B
MB
Bansal
E
E
Savage
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002939:Ciprofloxacin / Q000627:therapeutic use*; D002981:Clindamycin / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy* / Q000382:microbiology; D011446:Prospective Studies
D005839:Gentamicins; D002981:Clindamycin; D002939:Ciprofloxacin